BOULDER, Colo.--(BUSINESS WIRE)--Crosstrees Medical, Inc., a development stage company conducting clinical studies in the treatment of vertebral compression fractures, today announced that it has been granted a patent from the United States Copyright and Patent Office for its innovative delivery technology. The patent, U.S. Patent No. 7,993,343, was granted August 9, 2011 for "Extractable Filler for Inserting Medicine into Vertebral Body."
Research and Development staff at Crosstrees developed the patented technology to address the need for improved vertebral fracture repair devices that can potentially reduce risk of complications in vertebral augmentation procedures, such as nerve root compression, pulmonary embolism, and arterial embolism, reported in the published literature. Devices using Crosstrees PodTM technology feature a polymer material constructed to control the delivery of PMMA bone cement to the fracture site. Following PMMA delivery, the polymer construct is opened and removed from the vertebra, leaving only the filler material providing fracture fixation, pain relief, and stability.
"At Crosstrees, we are dedicated to improving the clinical outcomes of vertebral augmentation procedures for patients and our physician partners. The Crosstrees PodTM System offers performance benefits that may significantly improve surgical outcomes for patients with vertebral fractures," said Robert Scribner, President & CEO of Crosstrees Medical, Inc. "We are pleased with the issuance of this patent and the expansion of our defining intellectual property."
In the USA , the Crosstrees PodTM System is being evaluated in an IDE clinical study being conducted in support of a future 510(k) market clearance submission to the U.S. Food and Drug Administration (FDA). Details of the IDE study may be viewed at http://clinicaltrials.gov/ct2/show/NCT00933036?term=Crosstrees&rank=1. Estimates for the incidence of pathologic vertebral compression fractures in the USA by the National Osteoporosis Foundation exceed 700,000 annually. Crosstrees is developing and commercializing a product portfolio of that uses its patented extractable device technology to address the increasing demand for improved vertebral fracture treatment. The company has developed a portfolio of issued patents in the United States, EU, China, and Taiwan, with additional applications pending for a broad portfolio of therapeutic devices and methods of use.
For more information visit www.crosstreesmedical.com.
About Crosstrees Medical, Inc.:
Founded in 2003, Crosstrees Medical, Inc. is committed to the delivery of improved surgical techniques and procedure outcomes for vertebral fractures. The company is privately held and funded by Ascent Biomedical Ventures, Rho Ventures, and associated parties. For more information visit www.crosstreesmedical.com.